Stock Market Today: Nasdaq, S&P 500 Open Higher to Start Week; Novo Nordisk Plummets After Ozempic Alzheimer's Miss

Novo Nordisk's Ozempic pill has failed to demonstrate efficacy in slowing the progression of Alzheimer's disease in two clinical trials, leading to a significant decline in the company's stock value. This disappointing outcome was reported by Naomi Kresge on Bloomberg Television.

Shares of Novo Nordisk have significantly declined following the announcement that its Ozempic pill did not slow the progression of Alzheimer’s disease in two major studies. This news comes amid broader economic concerns, including a drop in German business morale as the country struggles to recover from two years of economic contraction.

Morgan Stanley strategist Michael Wilson expressed a bullish outlook for stocks in 2026, projecting the S&P 500 to reach 7,800. He emphasized the necessity for the Federal Reserve to implement rate cuts and highlighted the ongoing rally in AI stocks during an interview on Bloomberg Surveillance.

Ed Yardeni, founder and chief investment strategist at Yardeni Research, suggests that non-AI companies in the S&P 500 are poised for significant earnings growth, potentially overshadowing the so-called 'magnificent seven' tech firms that dominate the AI sector. He believes this shift could enhance the overall market value of these non-AI firms.

Morgan Stanley strategist Michael Wilson expressed concerns that the Federal Reserve is not acting swiftly enough in cutting interest rates, suggesting that further reductions are necessary. He anticipates a significant rally in the S&P 500, projecting it could reach 7,800 within a year, which is among the highest forecasts from Wall Street firms. Wilson shared these insights during an interview on Bloomberg Surveillance.

Shares of Novo Nordisk, the maker of Ozempic, have plummeted following the announcement that its medication failed to slow the progression of Alzheimer's disease in two significant clinical trials. This disappointing outcome has raised concerns about the company's future prospects in the Alzheimer's treatment market.

Novo Nordisk's stock has experienced a significant decline following the announcement that its diabetes and weight loss medication, Ozempic, failed to demonstrate any meaningful reduction in the progression of Alzheimer's disease in clinical trials. This disappointing outcome has raised concerns about the company's future prospects in the pharmaceutical market.

Novo Nordisk's shares have significantly declined following the announcement that its Ozempic medication failed to slow the progression of Alzheimer's disease in two major clinical trials. This outcome represents a substantial setback for one of Europe's largest listed companies, which had high hopes for the drug's efficacy in treating this debilitating condition.